Chiron/Searle Tifacogin Will Begin Two-Year, 1,500 Patient Trial In Sepsis

Chiron will initiate a pivotal, 1,500 patient trial of tifacogin in sepsis in the first half of the year, Chiron Chairman & CEO Sean Lance said during a Feb. 8 conference call announcing the company's sales and earnings for 1999.